astrazeneca - Search News

China, AstraZeneca

AstraZeneca overhauls management of its China division, FT reports

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct knowledge of the matter.

The Financial Times · 19h

AstraZeneca overhauls management of its scandal-hit China division

AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.

Seeking Alpha on MSN · 17h

AstraZeneca said to have changed management of its China unit

AstraZeneca (NASDAQ:AZN) has changed several key management positions in its China business as the Anglo-Swedish drugmaker looks to boost its sales following the recent detention of its President Leon Wang and several other scandals,

AstraZeneca, breast cancer

Reuters on MSN · 10h

US FDA approves AstraZeneca's drug for breast cancer

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,

Business Insider · 2h

FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer

The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab

MarketWatch · 10h

AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

15h

AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

21h

COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

FiercePharma17h

AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...

Harnessing AI and data science to discover life-changing medicines at AstraZeneca

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

16h

AstraZeneca rises Friday, still underperforms market

AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.

News Medical on MSN1d

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

16h

The Power of Personalized Breast Cancer Care

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

China, AstraZeneca

AstraZeneca, breast cancer

Related topics